Information Journal Paper
APA:
Copy. (2019). CDA and MTHFR polymorphisms are associated with clinical outcomes in gastroenteric cancer patients treated with capecitabine-based chemotherapy. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 83(5), 939-949. SID. https://sid.ir/paper/765404/en
Vancouver:
Copy. CDA and MTHFR polymorphisms are associated with clinical outcomes in gastroenteric cancer patients treated with capecitabine-based chemotherapy. CANCER CHEMOTHERAPY AND PHARMACOLOGY[Internet]. 2019;83(5):939-949. Available from: https://sid.ir/paper/765404/en
IEEE:
Copy, “CDA and MTHFR polymorphisms are associated with clinical outcomes in gastroenteric cancer patients treated with capecitabine-based chemotherapy,” CANCER CHEMOTHERAPY AND PHARMACOLOGY, vol. 83, no. 5, pp. 939–949, 2019, [Online]. Available: https://sid.ir/paper/765404/en